ADMA Biologics Announces Data on RI-002 to be Presented at

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
ADMA Biologics Announces Data on RI-002 to be Presented at the Clinical Immunology Society 2016 Annual Meeting

RAMSEY, N.J., April 12, 2016 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA ), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced that a poster titled “Protective Levels of Neutralizing Antibodies to Influenza are Present in an IVIG (RI-002) Containing Standardized and Elevated Levels of Neutralizing Antibodies to RSV and Can Protect Influenza Infected Cotton Rats,” will be presented at the Clinical Immunology Society 2016 Annual Meeting, being held April 14-17, 2016, in Boston, Massachusetts.

The data being presented will show that RI-002, ADMA’s lead product candidate, contains not only significantly elevated levels of neutralizing antibodies to RSV, but also significantly elevated levels of neutralizing antibodies to 5 different strains of influenza as tested in a laboratory of the Centers for Disease Control (CDC). In addition, the data presented will also demonstrate that RI-002 prevents infection in cotton rats challenged with influenza and suppresses inflammatory cytokines induced by influenza.

Details of the presentation are provided below.

Poster Number:  81 Poster Title: Protective Levels of Neutralizing Antibodies to Influenza are Present in an Intravenous Immune Globulin (IVIG) (RI-002) Containing Standardized and Elevated Levels of Neutralizing Antibodies to RSV and Can Protect Influenza Infected Cotton Rats Poster Hall Location: Commonwealth, Salon A Presentation Date and Time:  April 15 th from 12:30pm – 1:45pm and April 16 th from 12:45pm – 1:45pm.

The poster can be found on the ADMA website under drug development, posters and publications.

About ADMA Biologics, Inc. ADMA is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of Primary Immune Deficiency Disease (PIDD) and certain infectious diseases. ADMA's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. The target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for medical reasons. ADMA’s lead product candidate, RI-002, has completed a Phase III clinical trial in patients with PIDD and has met the primary endpoint, and a Biologics License Application (BLA) for RI-002 was accepted by the U.S. Food and Drug Administration (FDA) on September 18, 2015.  The company has received U.S. Patent 9,107,906.  For more information, please visit www.admabiologics.com .

About RI-002  ADMA's lead product candidate, RI-002, is a specialty plasma-derived, polyclonal, intravenous immune globulin (IGIV) derived from human plasma containing naturally occurring polyclonal antibodies (e.g., Streptococcus pneumoniae, H. influenza type B, cytomegalovirus (CMV), measles, tetanus, etc.) as well as standardized, high levels of antibodies to respiratory syncytial virus (RSV). ADMA is pursuing an indication for the use of this specialty intravenous immune globulin (IGIV) product for treatment of patients diagnosed with PIDD. Polyclonal antibodies are the primary active component of IGIV products. Polyclonal antibodies are proteins that are used by the body's immune system to neutralize microbes, such as bacteria and viruses. Data review indicates that the polyclonal antibodies present in RI-002 support its ability to prevent infections in immune-compromised patients. ADMA’s analysis demonstrated that the Phase III trial met the primary endpoint with no serious bacterial infections (SBI) reported. These results more than meet the requirement specified by the FDA guidance of ≤ 1 SBI per patient-year. 

About Primary Immune Deficiency Disease (PIDD) PIDD is a class of inherited genetic disorders that causes an individual to have a deficient or absent immune system due to either a lack of necessary antibodies or a failure of these antibodies to function properly. PIDD patients are more vulnerable to infections and more likely to suffer complications from these infections. According to the World Health Organization, there are over 150 different presentations of PIDD. As patients suffering from PIDD lack a properly functioning immune system, they typically receive monthly, outpatient infusions of IGIV therapy. Without this exogenous antibody immune support, these patients would be susceptible to a wide variety of infectious diseases. PIDD has an estimated prevalence of 1:1,200 in the United States, or approximately 250,000 people.

Forward-Looking Statements This press release contains "forward-looking statements" pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "target," "anticipate," "plan," "planning," "expect," "believe," "will," "will likely," “is likely”, "should," "could," "would," "may" or, in each case, their negative, or words or expressions of similar meaning. These forward-looking statements include, but are not limited to, statements concerning our plans and timing to develop, market and commercialize RI-002 and the success of such efforts, the expected timing of and our ability to obtain and maintain regulatory approvals for our product candidates, RI-002 containing significantly elevated levels of neutralizing antibodies to RSV, RI-002 containing elevated levels of neutralizing antibodies to 5 different strains of influenza, the ability of RI-002 to  prevent of infection in cotton rats challenged with influenza and suppresses inflammatory cytokines induced by influenza,  the timeframe within which we may receive approval from the FDA, if at all, of our BLA for RI-002, our ability to generate revenue, if any, from the potential commercialization of RI-002, if approved by the FDA, the timing, progress and results of the clinical development, our plans to increase our supplies of plasma, regulatory processes, interpretations of final data, possible characteristics of RI-002, acceptability of RI-002 for any purpose by physicians patients or payers,  concurrence by FDA with our conclusions and the satisfaction by us of its guidance,  the likelihood and timing of FDA action with respect to any further filings by the Company, results of the clinical development, continuing demonstrations of safety, comparability of results of RI-002 to other comparably run IVIG trials, improvements in clinical outcomes, potential of RI-002 to provide meaningful clinical improvement for patients living with PIDD, as well as to offer clinicians with an option for their immune compromised patients, market data and incidence of infection,  potential clinical trial initiations, potential investigational new product applications, biologics license applications, expansion plans, the achievement of clinical and regulatory milestones, commercialization efforts of the Company's product candidate(s) and trends relating to demand for source plasma. Forward-looking statements are subject to many risks and uncertainties that could cause our actual results and the timing of certain events to differ materially from any future results expressed or implied by the forward-looking statements, including, but not limited to, risks as to whether final and secondary data will be accepted as encouraging, positive or will otherwise lead to an effective or approved product, whether we will be able to demonstrate efficacy or gain necessary approvals to market and commercialize any product, whether the FDA will accept our data, accept our submission of BLAs, continue to recognize its previously reported guidance, grant a license, or approve RI-002 for marketing, whether we will meet or achieve any of our clinical,  regulatory or other milestones, whether we will develop any new products or expand existing ones, whether there may be changes in regional and worldwide supply and demand for source plasma, whether we will be able to attract sufficient donors and operate our new facility effectively or profitably, whether we can sell our plasma in the marketplace at prices that will lead to adequate amounts of revenue, whether we will be able to sustain the listing of our common stock on the NASDAQ Capital Market, whether we will meet any timing targets expressed by the Company, and other risks and uncertainties described in our filings with the U.S. Securities and Exchange Commission, including our most recent reports on Forms 10-K, 10-Q and 8-K, and any amendments thereto. Therefore, current and prospective security holders are cautioned that there also can be no assurance that the forward-looking statements included in this press release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation or warranty by ADMA or any other person that the objectives and plans of ADMA will be achieved in any specified time frame, if at all. Except to the extent required by applicable laws or rules, ADMA does not undertake any obligation to update any forward-looking statements or to announce revisions to any of the forward-looking statements.

Brian Lenz Vice President and Chief Financial Officer |201-478-5552 | www.admabiologics.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Vertiv's 800 VDC Push Gives AI Builders More Choices

Updated Category News Views 253

Electricity is becoming the awkward roommate inside every serious AI buildout, and Vertiv is trying to move it out of the rack before it eats the whole house. The company has expanded its 800 VDC offering beyond the PowerDirect 5000 rack product introduced in May 2026, laying out systems for the rack, the AI compute pod, and the full data hall. For investors following...

Continue Reading
PSEG Declares $0.67 Fourth-Quarter 2026 Cash Dividend

Updated Category News Views 112

A 67-cent utility dividend rarely sets the tape on fire, and that is precisely the point. Public Service Enterprise Group declared a regular fourth-quarter 2026 common-stock dividend of $0.67 per share, payable on or before December 31 to shareholders of record on December 10. For owners of NYSE:PEG, this is the sort of announcement that belongs in the “steady as she...

Continue Reading
Red Cat Stock Drama: Revenue Targets and Legal Waves

Updated Category News Views 110

Red Cat's Revenue Predictions Crash and Burn Sitting there on August 6, 2026, Red Cat Holdings had everyone believing they were on a fast track to hitting a hefty revenue target: $150–$180 million for FY2026. CEO Jeffrey Thompson didn't mince words, boasting confidence like a captain before a storm. Fast forward three months, and they're waving the white flag, tossing...

Continue Reading
UN Integrity Accelerator Targets Corporate Corruption

Updated Category News Views 10

Corruption rarely arrives wearing a villain costume; it shows up as a rushed payment, a friendly intermediary, or a contract nobody wants examined too closely. That is why the United Nations Global Compact's new Business Integrity Accelerator deserves a sober look. Launched November 18, 2026, the programme is not a magic shield, and nobody should sell it as one. But it...

Continue Reading
Animal Parasite Market Growth Has a Resistance Catch

Updated Category News Views 138

Flea collars and cattle worms do not sound glamorous, yet this is exactly where durable animal-health revenue gets built. Wissen Research puts the global animal parasiticides market at $13.6 billion in 2026 and projects $18.6 billion by 2031, a 6.5% compound annual growth rate. That is respectable, not moonshot stuff, and frankly that is part of the appeal. Pet owners...

Continue Reading
Historic China-Russia-US Summit Aims for Global Stability

Updated Category News Views 71

The Weight of History in Shenzhen When the big players decide to talk face-to-face, it's more than just a photo op. This week in Shenzhen, the leaders of China, Russia, and the United States are doing just that. And let me tell you, it's the kind of gathering that can either stabilize the gears of global politics or grease the wheels of tension. This chinwag isn't just...

Continue Reading
Lake Ridge's Strong Quarter Meets a Book Value Hit

Updated Category News Views 105

An $8.25-per-share securities markdown is the splinter in an otherwise sturdy third-quarter report from Lake Ridge Bancorp. The bank earned $9.8 million, or $4.97 per common share, for the quarter ended September 30, 2026. That is up from $9.0 million, or $4.59 per share, in the prior quarter and $7.7 million, or $3.94 per share, a year earlier. Those are not flimsy...

Continue Reading
Onward Therapeutics Secures $28M to Bolster Oncology R&D

Updated Category News Views 81

Cashing In to Conquer Cancer In the risk-laden world of biotech, Onward Therapeutics has just bagged a hefty NT$900 million—roughly US$28 million—from its Series B financing. That's not pocket change and speaks to the level of confidence their backers have, even as they plant their global headquarters firmly in Taipei since relocating from Switzerland. A Deep Dive...

Continue Reading
Visa Direct Tests Stablecoin Prefunding in Asia-Pacific

Updated Category News Views 103

Cross-border payouts have always had an ugly little problem: money can move digitally in theory, then sit around waiting for banks to wake up in practice. Triple-A’s new collaboration with Visa Direct aims straight at that nuisance in Asia-Pacific, allowing eligible clients to use stablecoins to prefund cross-border payouts while the recipient still gets local currency....

Continue Reading
Benicia's Bold Move to Streamline Permitting Pays Off

Updated Category News Views 147

Award-Winning Innovation from Benicia Benicia, California, shoots ahead of the pack by scooping up a highly coveted Helen Putnam Award for Excellence. Why? They chopped down bureaucracy like a lumberjack with a new ax by ushering in a digital revolution for their permitting process. Make no mistake, folks, this ain’t just a pat on the back—it's a blueprint for cities...

Continue Reading

Top 5 Most Recently Viewed Articles

Transforming $100 into a Remarkable Asset with ISRG

Updated Category News Views 310

Investing in Intuitive Surgical: A Decade of Growth Investing in stocks can often lead to impressive returns, and when it comes to Intuitive Surgical (NASDAQ: ISRG), this statement holds particularly true over the past decade. With a remarkable annualized return of 24.63%, Intuitive Surgical has substantially outperformed the market, making it an attractive consideration...

Continue Reading
Giftify, Inc. Empowers Consumers Amid Increasing Food Costs

Updated Category News Views 181

How Giftify, Inc. is Supporting Consumers with Savings In a time where food prices are skyrocketing, especially in the grocery sector, Giftify, Inc. (NASDAQ: GIFT), the company behind the CardCash.com platform, is stepping up to support consumers. With rising egg prices and the increasing impact of inflation, Giftify is providing a practical solution for everyday...

Continue Reading
HCA Healthcare Posts Strong Results, Showcases Growth Potential

Updated Category News Views 315

HCA Healthcare Inc. Surpasses Expectations with Q3 Results HCA Healthcare Inc. (NYSE: HCA), recognized as one of the largest hospital operators in the country, recently shared its financial results for the third quarter of 2025. The company reported a notable increase in its financial metrics, showcasing resilience and growth amidst the evolving healthcare landscape....

Continue Reading
MedEx Ambulance Addresses Security Incident Resolution Steps

Updated Category News Views 379

Understanding the Recent Data Security Incident MedEx Ambulance, known for its dedication to emergency services, has recently faced a troubling data security incident. This incident has raised concerns about unauthorized access to both patient health records and employee personal details. Although operations have continued without disruption, MedEx feels it's crucial to...

Continue Reading
Blue Apron Tops Rankings for Home Meal Delivery Services

Updated Category News Views 139

Blue Apron Achieves Top Rank for Home Meal Delivery Blue Apron has risen to the highest rank for home-cooked meals through an extensive evaluation by Expert Consumers. This independent assessment focused on various meal delivery services, gauging them based on ingredient quality, recipe clarity, sourcing transparency, ease of use, and overall support for home cooking. Why...

Continue Reading